Orthopedic surgery

Wireless Testing Market worth $34.1 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, March 28, 2024
Health, Viavi Solutions, Transport, Statistics, WCDMA, LTE, Internet of things, Rohde & Schwarz, WLAN, Measurement, City, Code-division multiple access, Orthopedic surgery, Keysight, Region, OTA, Medicine, GSM, Wireless, Bureau Veritas, SGS S.A., WiMAX, CDMA, HSPA, UMTS, Construction, Growth, Final good, DEKRA, Telecommunications, IVD, Agriculture, Hardware, Bluetooth, Mobile phone

The Wireless network testing by equipment segment is expected to account for the largest share of the wireless testing market in 2024.

Key Points: 
  • The Wireless network testing by equipment segment is expected to account for the largest share of the wireless testing market in 2024.
  • The wireless network testing segment is a significant market for wireless testing.
  • The IT & telecommunication segment is expected to account for the largest share of the wireless testing market in 2024.
  • The Asia Pacific market is expected to witness the highest CAGR in the wireless testing market during the forecast period.

Wireless Testing Market worth $34.1 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, March 28, 2024
Health, Viavi Solutions, Transport, Statistics, WCDMA, LTE, Internet of things, Rohde & Schwarz, WLAN, Measurement, City, Code-division multiple access, Orthopedic surgery, Keysight, Region, OTA, Medicine, GSM, Wireless, Bureau Veritas, SGS S.A., WiMAX, CDMA, HSPA, UMTS, Construction, Growth, Final good, DEKRA, Telecommunications, IVD, Agriculture, Hardware, Bluetooth, Mobile phone

The Wireless network testing by equipment segment is expected to account for the largest share of the wireless testing market in 2024.

Key Points: 
  • The Wireless network testing by equipment segment is expected to account for the largest share of the wireless testing market in 2024.
  • The wireless network testing segment is a significant market for wireless testing.
  • The IT & telecommunication segment is expected to account for the largest share of the wireless testing market in 2024.
  • The Asia Pacific market is expected to witness the highest CAGR in the wireless testing market during the forecast period.

NRMP® Celebrates Match Day for the 2024 Main Residency Match®, Releases Results for Over 44,000 Applicants and Almost 6,400 Residency Programs

Retrieved on: 
Friday, March 15, 2024
Interventional radiology, PGY-1, Internal medicine, Growth, Pathology, Med-Peds, COVID-19, Anne Ferguson-Smith, Internal, Emergency medicine, MD, MBA, Competition (economics), Cardiothoracic surgery, Orthopedic surgery, BSN, Acceptance, Workforce, Physician, Doctor of Health Science, NRMP, Nursing

This year's Match included 44,853 applicants who certified a rank order list ("active applicants") and 41,503 certified positions in 6,395 residency training programs.

Key Points: 
  • This year's Match included 44,853 applicants who certified a rank order list ("active applicants") and 41,503 certified positions in 6,395 residency training programs.
  • A total of 50,413 applicants registered in the 2024 Main Residency Match, an all-time high and increase of 2,257 or 4.7 percent over last year.
  • Increases afforded applicants access to 125 more programs and 1,128 positions which is 2.8 percent more than the 2023 Main Residency Match.
  • Detailed SOAP results will be available in the 2024 Main Residency Match Results and Data Book, which is published in the Spring.

Testing, Inspection, and Certification Market worth $280.7 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, March 15, 2024
UL, Quality control, Textile testing, TIC, ASTM, UL LLC, Spectrum, Statistics, NAFTA, Measurement, Safety, Orthopedic surgery, Intertek, Medicine, Bureau Veritas, SGS, Digital technology, DNV, Construction, Final good, ALS, IVD, Oil analysis, Ecosystem, Medical device

Testing, inspection, and certification services are crucial across various industries to ensure compliance with standards and regulations.

Key Points: 
  • Testing, inspection, and certification services are crucial across various industries to ensure compliance with standards and regulations.
  • The adoption of digital technology is a prominent trend among industry leaders like SGS, Intertek, and Bureau Veritas, expected to drive market growth.
  • With expanding global trade and regulatory requirements, coupled with manufacturers' focus on digitalization, outsourcing of testing, inspection, and certification services is on the rise.
  • North America is expected to hold the second-largest share of the testing, inspection, and certification market during the forecast period.

Testing, Inspection, and Certification Market worth $280.7 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, March 15, 2024
UL, Quality control, Textile testing, TIC, ASTM, UL LLC, Spectrum, Statistics, NAFTA, Measurement, Safety, Orthopedic surgery, Intertek, Medicine, Bureau Veritas, SGS, Digital technology, DNV, Construction, Final good, ALS, IVD, Oil analysis, Ecosystem, Medical device

Testing, inspection, and certification services are crucial across various industries to ensure compliance with standards and regulations.

Key Points: 
  • Testing, inspection, and certification services are crucial across various industries to ensure compliance with standards and regulations.
  • The adoption of digital technology is a prominent trend among industry leaders like SGS, Intertek, and Bureau Veritas, expected to drive market growth.
  • With expanding global trade and regulatory requirements, coupled with manufacturers' focus on digitalization, outsourcing of testing, inspection, and certification services is on the rise.
  • North America is expected to hold the second-largest share of the testing, inspection, and certification market during the forecast period.

MDpanel Names Dr. Sonu Ahluwalia to Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Sonu, Business, Orthopedic surgery, University, Patient, MBA, Harvard University, QME, Physician, Medical director

LOS ANGELES, March 13, 2024 /PRNewswire/ -- MDpanel is pleased to announce that Dr. Sonu Ahluwalia has joined its Board of Directors.

Key Points: 
  • LOS ANGELES, March 13, 2024 /PRNewswire/ -- MDpanel is pleased to announce that Dr. Sonu Ahluwalia has joined its Board of Directors.
  • Dr. Ahluwalia is Vice Chair and Medical Director in the Department of Orthopaedic Surgery and a member of the Cedars-Sinai Medical Center Board of Directors.
  • He held residency and fellowships at Harvard University and earned an MBA from the Wharton School of Business at the University of Pennsylvania.
  • MDpanel can help physicians alleviate these pressures while contributing substantially to the well-being of patients.

Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection

Retrieved on: 
Wednesday, March 13, 2024
USP, Infection, Debridement, Hip, Genetically modified bacteria, Surgeon, Wound healing, Orthopedic surgery, Traumatology

KEELE, England, March 13, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the approval in Brazil of STIMULAN as a calcium matrix antibiotic carrier for use in wound healing and the treatment of bacterial infection.

Key Points: 
  • Brazil joins a growing list of more than 60 countries around the world where STIMULAN is the only calcium matrix approved to carry antibiotics in bone and soft tissue.
  • This approval gives surgeons in Brazil, a country of 217 million people, the flexibility to select and source their preferred choice of antibiotic to suit each patient-specific treatment plan.
  • STIMULAN enables high concentrations of antibiotic to be applied at the point of infection, leading to reduced rates of reinfection, decreased hospital readmissions, and significantly improved patient outcomes.
  • We use STIMULAN concomitantly with the antibiotic vancomycin to completely fill the bone lesion, following debridement, and close with full soft tissue coverage."

Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection

Retrieved on: 
Wednesday, March 13, 2024
USP, Infection, Debridement, Hip, Genetically modified bacteria, Surgeon, Wound healing, Orthopedic surgery, Traumatology

KEELE, England, March 13, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the approval in Brazil of STIMULAN as a calcium matrix antibiotic carrier for use in wound healing and the treatment of bacterial infection.

Key Points: 
  • Brazil joins a growing list of more than 60 countries around the world where STIMULAN is the only calcium matrix approved to carry antibiotics in bone and soft tissue.
  • This approval gives surgeons in Brazil, a country of 217 million people, the flexibility to select and source their preferred choice of antibiotic to suit each patient-specific treatment plan.
  • STIMULAN enables high concentrations of antibiotic to be applied at the point of infection, leading to reduced rates of reinfection, decreased hospital readmissions, and significantly improved patient outcomes.
  • We use STIMULAN concomitantly with the antibiotic vancomycin to completely fill the bone lesion, following debridement, and close with full soft tissue coverage."

AOFAS Honors Two Female Orthopaedic Leaders

Retrieved on: 
Tuesday, February 27, 2024
Stamford Hospital, Treace Medical Concepts, Breast cancer, Cancer, Weill Cornell Medicine, Woman, Copy, Ankle, Medical school, Assistant, Physician, Hospital, Female, Fluoroscopy, Surgeon, NewYork-Presbyterian Hospital, Orthopedic surgery, Radiation, Risk, Stanford University, Breast, Prevalence, Operating, Knowledge, New York Medical College, Male, Publication, DRS, Research, Dentistry

“I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”

Key Points: 
  • “I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”
    Over the past 15 years, Dr. Chou has conducted several research studies to examine breast cancer prevalence among female orthopaedic surgeons.
  • Dr. Chou’s research results confirmed higher breast cancer prevalence among female orthopaedic surgeons than the general population, and in a later study, she discovered higher prevalence among female orthopaedic surgeons compared to women in other surgical specialties.
  • Currently, she is leading a study to evaluate cancer risk associated with radiation exposure in male and female orthopaedic surgeons.
  • I applaud AOFAS for taking that initiative with these awards.”
    Funding for the AOFAS Women’s Leadership Initiative is provided by the Orthopaedic Foot & Ankle Foundation, supported by a grant from Treace Medical Concepts, Inc.

Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Therapy, Regeneration, EVP, Multimedia, MD, Neuropathic pain, Physician, FDA, Standard of care, Orthopedic surgery, MHQ, Safety, Associate, Nerve, Patient, Sympathetic nervous system, Lead author

At the 24-week mark, NTX-001 continues to demonstrate an encouraging safety profile, with lower treatment-emergent adverse event rates than the standard of care.

Key Points: 
  • At the 24-week mark, NTX-001 continues to demonstrate an encouraging safety profile, with lower treatment-emergent adverse event rates than the standard of care.
  • The secondary endpoints, including the Numerical Pain Rating Scale, also showed statistically significant improvements, favoring NTX-001 at the 24-week timepoint.
  • Neuraptive Therapeutics, Inc. is dedicated to the innovation and development of medical products and therapeutics to repair and regenerate peripheral nerves.
  • Neuraptive Therapeutics, Inc. disclaims any obligation to update the information contained in these forward-looking statements.